Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

Upon his return to the United States Presidency, Donald Trump signed a number of executive orders that will not have an immediate impact, but will take effect in the coming weeks.

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but expensive weight-loss drugs.

Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid agencies to research and implement models for lowering the costs of prescription drugs. Separate provisions in the Inflation Reduction Act of 2022 also aimed at lower prescription drug costs are still in effect.

Trump’s early health orders signal plans to reverse Biden policies on drug prices and Medicaid. Experts predict more uninsured but await further action.

The Trump administration came into office earlier this week with a promise of cutting down on government spending and driving greater efficiency, but a new poll from KFF shows voters largely support continued spending on Medicare and Medicaid.

Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.

President Donald Trump began his second administration with a blitz of policy actions to reorient U.S. government priorities.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...